Moens de Hase, Emilie
Neyrinck, Audrey M. http://orcid.org/0000-0002-9435-3338
Rodriguez, Julie http://orcid.org/0000-0002-8271-3893
Cnop, Miriam http://orcid.org/0000-0002-5112-1692
Paquot, Nicolas
Thissen, Jean-Paul http://orcid.org/0000-0001-9165-0364
Xu, Yining
Beloqui, Ana http://orcid.org/0000-0003-4221-3357
Bindels, Laure B. http://orcid.org/0000-0003-3747-3234
Delzenne, Nathalie M. http://orcid.org/0000-0003-2115-6082
Van Hul, Matthias http://orcid.org/0000-0002-5503-107X
Cani, Patrice D. http://orcid.org/0000-0003-2040-2448
Funding for this research was provided by:
Service Public de Wallonie (FOOD4gUT 518 project, convention 1318148)
Action de Recherche Concertée (ARC19/24-096)
'la Caixa' Foundation (NeuroGut)
Fonds De La Recherche Scientifique - FNRS (CDR-convention: J.0027.22, EOS: program no. 40007505, FNRS T.0030.21, PDR T.0068.19, PINT-MULTI R.8013.19, WELBIO-CR-2022A-02)
Article History
Received: 8 June 2023
Accepted: 11 September 2023
First Online: 28 October 2023
Acknowledgements
: We thank A. Puel, H. Danthinne, M. Olivier, B. Es Saadi, L. Gesche and R. M. Goebbels (at UCLouvain, Université catholique de Louvain) for their excellent technical support and assistance. AB is a research associate and PDC is honorary research director at FRS-FNRS (Fonds de la Recherche Scientifique). We thank T. Le Roy (formerly a WELBIO post doc at UCLouvain) for help during the culture used for the GLP-1 in vitro cell assay.
: All the data contained within this article are available within the paper. All the participant characteristics and markers measured in the human trial are available in Rodriguez et al [CitationRef removed] and Hiel et al [CitationRef removed]. The trial protocol was published on protocols.io (dx.doi.org/10.17504/protocols.io.baidica6). The raw data on mice will be shared upon reasonable request: Contact Patrice D. Cani (UCLouvain, patrice.cani@uclouvain.be).
: Food4Gut was supported by the competitive cluster Wagralim from Wallonia (Food4Gut 518 project, convention 1318148). NMD is a recipient of grants from the Fonds de la Recherche Scientifique (FRS-FNRS, convention PINT-MULTI R.8013.19 [NEURON, call 2019] and convention PDR T.0068.19). PDC is a recipient of grants from the FNRS (Projet de Recherche PDR-convention: FNRS T.0030.21, CDR-convention: J.0027.22, FRFS-WELBIO: WELBIO-CR-2022A-02, EOS: program no. 40007505), ARC (Action de recherche concertée: ARC19/24-096) and La Caixa (NeuroGut). The study funders were not involved in the design of the study; the collection, analysis and interpretation of data; or writing of the report; and did not impose any restrictions regarding the publication of the report.
: PDC and EMdH are inventors on patent applications dealing with the use of specific bacteria and components in the treatment of different diseases. PDC was co-founder of The Akkermansia Company SA and Enterosys. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors contributed to the design of the clinical study, collection of samples and interpretation of the results. EMdH, PDC, MVH, AMN and NMD contributed to data management and data analyses of the human study. EMdH, PDC and MVH contributed to data collection, management and data analyses of the mouse experiments. PDC and MVH wrote the first draft of the manuscript. All authors reviewed and edited the first draft of the manuscript. All authors approved the final version of the manuscript. PDC and MVH are the guarantors of this work.